• column
  • column
    • Home
    • About Us
      • Our vision
      • Our team
      • Our founders
      • Scientific Advisory Board
      • News & Resources
      • Case Studies
      • Clients
  • column
    • Our Services
      • How we work
      • Project partners
    • Preclinical Research Services
    • Clinical Trial Volunteer Opportunities
    • Clinical Trials Services
  • column
    • Contact
      • Companies
      • Volunteers
    • FOLLOW US
      • X
      • Linkedin
      • Facebook
Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations.

Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations.

by Virtus | Nov 6, 2019

Click the button below to read more about this. CLICK HERE FOR...
Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production.

Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production.

by Virtus | Nov 3, 2019

Click the button below to read more about this. CLICK HERE FOR...
Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation.

Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation.

by Virtus | Nov 3, 2019

Click the button below to read more about this. CLICK HERE FOR...
Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease.

Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease.

by Virtus | Nov 3, 2019

Click the button below to read more about this. CLICK HERE FOR...
Oxidative and nitrosative stress and histone deacetylase-2 activity in exacerbations of COPD.

Oxidative and nitrosative stress and histone deacetylase-2 activity in exacerbations of COPD.

by Virtus | Nov 3, 2019

Click the button below to read more about this. CLICK HERE FOR...
« Older Entries
Next Entries »

Recent Posts

  • Asthma Drug Development: Advancing New Treatments for Respiratory Disease
  • Respiratory Disease Models: Understanding the Foundation of Preclinical Respiratory Research
  • Respiratory Drug Development: From Discovery to Clinical Trials
  • Preclinical Respiratory Models: A Guide to Asthma, COPD and Viral Disease Research
  • Rhinovirus vs RSV vs influenza preclinical models

Recent Comments

No comments to show.

Privacy Notice and Cookie Policy





All content © 2022 Virtus Respiratory Research. All Rights Reserved.

Contact